Seattle’s Deverra Therapeutics Raises $2.4M to Develop Cellular Immunotherapies with Fred Hutch License

Seattle biotech startup Deverra Therapeutics, founded by oncologist Colleen Delaney, is raising $2.4 million through debt and warrants to advance its cellular immunotherapy platform licensed from Fred Hutch. The company recently secured $3.5 million from the Andy Hill CARE Fund and licensed an immuno-oncology platform from Coeptis Therapeutics for $570,000 plus shares.